Private equity firms go after covid-19, repurposing portfolio company resources

While many traditional PE shops are busy assessing the potential impacts of covid-19 on their portfolios, a few are turning to their companies to develop vaccines and tests to curb the spread of coronavirus.

DealsNorth AmericaUSHealthcareCoronavirusFeaturedTop Stories